The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...
Updated results from the phase 3 XTEND-1 trial were presented at ISTH, once again comparing the therapy to patients' previous treatment with clotting factor replacement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback